Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Nature | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25425644 | 2015 | {nnr:T1}-VVLVGIAGVALVV- {nnr:T2} | TM4(88–100)scr | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH7 | 13 | Antimicrobial | Not specified | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIV{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100) | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH8 | 13 | Antimicrobial | 10 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIG{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100)-G95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH9 | 13 | Antimicrobial | 10 % Hemolysis at 25 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIN{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH10 | 13 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-V{nnr:X'}GLALIN{nnr:X}GVVV-{nnr:T2} | S1-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH11 | 13 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X'}LINAGV{nnr:X}V-{nnr:T2} | S2-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH12 | 13 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Synthetic | α-Helical | NA | ||
| 28230992 | 2017 | LRRLRRRLRRLRRRWRRRLRRLRRRLRRL{ct:Amid} | 6 | Amidation | Free | Branched | L | None | 29 | Antibacterial | 10 % Hemolysis at 64 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRLRRLRRRLRRLRRRWRRRLRRLRRRLRRLRRRLRRL{ct:Amid} | 7 | Amidation | Free | Branched | L | None | 43 | Antibacterial | 10 % Hemolysis at 64 mg/L | Human | Synthetic | α-Helix | NA | ||
| 29473887 | 2018 | (KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF){nnr:4-arm-PEG-PLGA} | cathelicidin-BF-30loaded 4-arm-PEG-PLGA | Free | Free | NA | L | 4-arm-PEG-PLGA = ethylene glycol-b-dl-lactic acid-co-glycolic acid(microspheres) | 30 | Antimicrobial | ~15 % Hemolysis at 1000 μg/mL | Rabbit | Snake Venoms Of Bungarus Fasciatus | α-Helical | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRK{nnr:Ahx} | Dimeric (LfcinB (20–25)2) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 15 | Antibacterial | 5.6 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRRRWQWRRRWQWRKK{nnr:Ahx}{nnr:Ahx}CC | Tetrameric (LfcinB (20–25)4) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 30 | Antibacterial | 49.1 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRK{nnr:Ahx} | Dimeric (LfcinB (20–25)2) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 15 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRRRWQWRRRWQWRKK{nnr:Ahx}{nnr:Ahx}CC | Tetrameric (LfcinB (20–25)4) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 30 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29275987 | 2018 | KKKKKK-AAF{nnr:X}AWA{nnr:X}FAA{nt:6 Lys}{ct:Amid} | S-6K-F17 | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | 2 % Hemolysis at 4 µM | Human | 6K-F17 Hydrocarbon Staple | Random coil | NA | ||
| 29275987 | 2018 | KKKKKK-AGF{nnr:X}AWA{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-2G | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 15[5.8] µM | Human | 6K-F17 Hydrocarbon Staple | NA | NA | ||
| 29275987 | 2018 | KKKKKK-AGF{nnr:X}AWG{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-3G | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 128[43.8] µM | Human | 6K-F17 Hydrocarbon Staple | Random coil | NA | ||
| 29275987 | 2018 | KKKKKK-NGF{nnr:X}AWG{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-3GN | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 587[130.6] µM | Human | 6K-F17 Hydrocarbon Staple | Helical | NA | ||
| 29770868 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ-({nnr:Dab}-NH2)-GIGAVLKVLTTGLPALISWIKRKRQQ | melittin dimer | Free | Free | Branched | L | Dab = 3,3ʹ-diaminobenzidine | 52 | Antibacterial | 100 % Hemolysis at 10 μM | mouse | Synthetic Dimer Of Melittin | NA | NA | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKKLKKLKKL | L-G3KL | Free | Free | Branched | L | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d} | D-G3KL | Free | Free | Branched | D | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | OFOFOFOFKBLKBLKKLK{ct:C10} | L-TNS18 | Free | Free | Branched | L | None | 18 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | O{d}F{d}O{d}F{d}O{d}F{d}O{d}F{d}K{d}B{d}L{d}K{d}B{d}L{d}K{d}K{d}L{d}K{d}{ct:C10} | D-TNS18 | Free | Free | Branched | D | None | 18 | Antibacterial. Antibiofilm | MHC at 500 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Low hemolytic | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKLLKLLKKLL | L-T25 | Free | Free | Branched | L | None | 38 | Antibacterial. Antibiofilm | MHC at 62.5 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | NA | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}L{d}L{d}K{d}L{d}L{d}K{d}K{d}L{d}L{d} | D-T25 | Free | Free | Branched | D | None | 38 | Antibacterial. Antibiofilm | MHC at 125 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 9.1 % Hemolysis at 64 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 4 % Hemolysis at 32 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.8 % Hemolysis at 16 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.4 % Hemolysis at 8 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | G-{nnr:S5}-LKR-{nnr:S5}-KTLL{ct:Amid} | Anoplin[2-6] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 2.1 % Hemolysis at 4 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 62.7 % Hemolysis at 64 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 43.2 % Hemolysis at 32 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 29.8 % Hemolysis at 16 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 16.6 % Hemolysis at 8 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 34966367 | 2021 | GLLK-{nnr:S5}-IKT-{nnr:S5}-L{ct:Amid} | Anoplin[5-9] | Amidation | Free | Stapled | L | S5 = Olefinic | 8 | Antibacterial | 6.5 % Hemolysis at 4 μM | Sheep | Anoplin Analogs | phosphate buffer = α-Helical, membrane-mimicking environments = α-Helical | NA | ||
| 35203875 | 2022 | RR{nnr:S5}FRR{nnr:S5}LRWL | L6S1 | Free | Free | Macrocyclized | L | (R8) and (S5) indicate stapled using 8- and 5-atom linkers, respectively. | 11 | Antibacterial | ∼5 % Hemolysis at 50 µM | Sheep | Synthetic | NA | Non-hemolytic | ||
| 35203875 | 2022 | RRLFRR{nnr:S5}LRW{nnr:S5} | L6S2 | Free | Free | Macrocyclized | L | (S5) and (S5) indicate stapled using 5- and 5-atom linkers, respectively. | 11 | Antibacterial | ∼55 % Hemolysis at 50 µM | Sheep | Synthetic | NA | NA | ||
| 35203875 | 2022 | RRL{nnr:R8}RRILRW{nnr:S5} | L6S3 | Free | Free | Macrocyclized | L | (R8) and (S5) indicate stapled using 8- and 5-atom linkers, respectively. | 11 | Antibacterial | <5 % Hemolysis at 50 µM | Sheep | Synthetic | NA | Non-hemolytic | ||
| 35203875 | 2022 | KRI{nnr:R8}QRIKKW{nnr:S5}R | L8S3 | Free | Free | Macrocyclized | L | (R8) and (S5) indicate stapled using 8- and 5-atom linkers, respectively | 12 | Antibacterial | ∼20 % Hemolysis at 50 µM | Sheep | Synthetic | NA | Non-hemolytic | ||
| 35335979 | 2022 | KKWVPWKKKWVPWKKIANIL{ct:Amid} | T1CEh-KKPWW2 | Amidation | Free | Branched | L | None | 20 | Antibacterial, Antibiofilm | 63 % Hemolysis at 256 µM | Horse | Synthetic | α-Helix | NA | ||
| 35464194 | 2022 | VKRF{nnr:S5}KFF{nnr:S5}KLKKLV{ct:Amid} | B1-L-2 | Amidation | Free | Stapled | L | S5 = (S)-2-(4-pentenyl) alanine, stapled b/w S5 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35464194 | 2022 | VKRFK{nnr:S5}FFR{nnr:S5}LKKLV{ct:Amid} | B1-L-3 | Amidation | Free | Stapled | L | S5 = (S)-2-(4-pentenyl) alanine, stapled b/w S5 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35464194 | 2022 | VKRFKKFF{nnr:S5}KLK{nnr:S5}LV{ct:Amid} | B1-L-4 | Amidation | Free | Stapled | L | S5 = (S)-2-(4-pentenyl) alanine, stapled b/w S5 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35464194 | 2022 | V{nnr:R8}RFKKFF{nnr:S5}KLKKLV{ct:Amid} | B1-L-5 | Amidation | Free | Stapled | L | S5 = (S)-2-(4-pentenyl) alanine, stapled b/w R8 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35464194 | 2022 | VKRF{nnr:R8}KFFRKL{nnr:S5}KLV{ct:Amid} | B1-L-6 | Amidation | Free | Stapled | L | R8 = (R)-2-(7-octenyl) alanine, S5 = (S)-2-(4-pentenyl) alanine, stapled b/w R8 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35464194 | 2022 | VKRFK{nnr:R8}FFRKLK{nnr:S5}LV{ct:Amid} | B1-L-7 | Amidation | Free | Stapled | L | R8 = (R)-2-(7-octenyl) alanine, S5 = (S)-2-(4-pentenyl) alanine, stapled b/w R8 and S5 | 15 | Antibacterial, Cytotoxic | 50 % Hemolysis at > 80 µM | Rabbit | Bungarus Fasciatus | NA | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKVARRTVAKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | WT | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 0.12 ± 0.07 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 2 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 6.6 ± 0.3 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKVARR{nnr:X}VAK{nnr:X}RE{nnr:NIe}L{nt:Acet}{ct:Amid} | 10 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 10.7 ± 0.3 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}|{nt:Acet}{ct:Amid} | 14 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 35.0 ± 0.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}KRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 17 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 3.3 ± 0.7 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RKT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 18 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 3.3 ± 0.05 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}GKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 31 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 0.53 ± 0.05 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FRV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 33 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 1.5 ± 0.03 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFKK-FLSGIVGMLDAKLF-FLSGIVGMLDAKLF{ct:Amid} | [G10a]3 SHa | Amidation | Free | Branched | Mix | a = D-alanine, Linked b/w Lys27 and Phe27 | 41 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 10.46 ± 0.36 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFKK-FLSGIVGMLDAKLF-FLSGIVGMLDAKLF{ct:Amid} | [G10a]3 SHa | Amidation | Free | Branched | Mix | a = D-alanine, Linked b/w Lys27 and Phe27 | 41 | Antimicrobial, Antiproliferative | 100 % Hemolysis at 100 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA |